Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 26.10.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. WO2015055825 - METHOD FOR DIAGNOSIS OF PRIMARY HYPERALDOSTERONISM

Publication Number WO/2015/055825
Publication Date 23.04.2015
International Application No. PCT/EP2014/072339
International Filing Date 17.10.2014
IPC
G01N 33/74 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
74involving hormones
CPC
A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/401
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
401Proline; Derivatives thereof, e.g. captopril
A61K 31/4178
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61P 5/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
38of the suprarenal hormones
G01N 2333/723
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
72for hormones
723Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
G01N 2410/02
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2410Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
02Angiotensins; Related peptides
Applicants
  • ATTOQUANT DIAGNOSTICS GMBH [AT]/[AT]
Inventors
  • POGLITSCH, Marko
  • SCHWAGER, Cornelia
  • VAN OYEN, Dunja
  • LEITNER, Martin
Agents
  • SONN & PARTNER PATENTANWÄLTE
Priority Data
13189386.918.10.2013EP
14152763.028.01.2014EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR DIAGNOSIS OF PRIMARY HYPERALDOSTERONISM
(FR) PROCÉDÉ DE DIAGNOSTIC D'HYPERALDOSTÉRONISME PRIMAIRE
Abstract
(EN)
The present invention relates to methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.
(FR)
L'invention concerne des procédés et des kits pour diagnostiquer l'hyperaldostéronisme primaire (PHA). En particulier, la présente invention concerne l'utilisation d'un nouveau paramètre de diagnostic qui est composé du rapport entre le niveau d'Ang II, en particulier le niveau d'Ang II à l'équilibre à l'état stable, et le niveau d'aldostérone dans un échantillon biologique, comme par exemple du plasma. Le rapport des deux paramètres mesurés est utilisé pour diagnostiquer la PHA chez des patients et a des avantages évidents par rapports aux procédés de diagnostic actuellement utilisés.
Latest bibliographic data on file with the International Bureau